Molecular Enzymology and Drug Targets

  • Journal h-index: 5
  • Journal CiteScore: 0.49
  • Journal Impact Factor: 0.48
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • Publons
  • Google Scholar
  • Secret Search Engine Labs
Share This Page
Recommended Webinars & Conferences

Viyanka Amoria

Department of Physics and Biophysics, University of Varmia & Masuria in Olsztyn, 4 Oczapowskiego St., 10-719 Olsztyn, Poland

  • Mini Review   
    Enzymes and Drug Targets: Transition State Enzyme Inhibitors
    Author(s): Viyanka Amoria*

    Enzyme inhibitors or inactivators are a common class of drugs used to treat cancer, inflammatory, cardiovascular, metabolic, and infectious diseases. Models exist for every one of the six classes of catalysts, however inhibitors of hydrolases, transferases, and oxidoreductases prevail. At concentrations of 100 nanomolars or less, enzyme inhibitors or inactivators that eventually become drugs typically have a high selectivity for their targets and a high potency toward their targets. Thirteen ribozymes make up the human CYP4 family of enzymes, which typically catalyse the -oxidation of endogenous fatty acids and eicosanoids. 20-HETE, a crucial signalling eicosanoid involved in regulating vascular tone and kidney reabsorption, can be biosynthesized by several CYP4 enzymes. Additionally, the rare genetic disorders Refsum disease and X-ALD are characterized by the accumulation of particul.. View More»

    DOI: 2572-5475- 08.06-120

    Abstract HTML PDF